跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
ICI-1
首页
药物
ICI-1
ICI-1
未知生产厂商
订阅
生成 AI 研报
Share to Twitter
Share to Facebook
Share to LinkedIn
Share to Reddit
摘要
临床试验
审批记录
专利
每项发明一条,涵盖美国、欧洲、PCT 与中国的同族专利。
COMBINED USE OF UBENIMEX AND IMMUNE CHECKPOINT INHIBITOR
US 2024082196 A1
申请人: NIPPON KAYAKU KK
优先权: 2021
CN
US
2 件公开
GLUCOCORTICOID RECEPTOR BLOCKADE WITH MIFEPRISTONE TO SENSITIZE PANCREATIC CANCER TO IMMUNOTHERAPY
US 20250032506 A1
申请人: UNIV TEXAS
优先权: 2021
CN
US
2 件公开
SYK INHIBITORS FOR USE IN THE TREATMENT OF IMMUNE CHECKPOINT INHIBITION INDUCED ADVERSE EVENTS
EP 4520333 A1
申请人: UNIV FREIBURG ALBERT LUDWIGS
优先权: 2023
EP
WO
2 件公开
VIRAL VECTORS FOR TREATING CANCER IN IMMUNE CHECKPOINT INHIBITOR-REFRACTORY SUBJECTS
EP 4795184 A1
申请人: CANDEL THERAPEUTICS INC
优先权: 2023
EP
WO
2 件公开
多元羧酸缩合体及其制造方法、环氧树脂用固化剂及其制造方法以及聚酰胺树脂、聚酯树脂
CN 104650020 B
申请人: 日立化成株式会社
优先权: 2008
CN
IDENTIFICATION OF PATHOGENIC IMMUNE CELL SUBSETS IN CHECKPOINT INHIBITOR-INDUCED MYOCARDITIS
US 20250026848 A1
申请人: U S GOVERNMENT AS REPRESENTED BY THE DEPT OF VETERANS AFFAIRS
优先权: 2022
US
FECAL MICROBIOTA TRANSPLANTATION OVERCOMES RESISTANCE TO IMMUNOTHERAPY IN GASTROINTESTINAL CANCER PATIENTS
WO 2025149085 A1
申请人: SHENZHEN XBIOME BIOTECH CO LTD
优先权: 2024
WO
USE OF CARDIAC AUTOANTIBODIES AS A METHOD TO IDENTIFY INDIVIDUALS AT INCREASED RISK OF DEVELOPING CARDIOVASCULAR EVENTS
WO 2025174781 A1
申请人: JOSLIN DIABETES CENTER INC
优先权: 2024
WO
CD16A/TUMOR ANTIGEN POLYSPECIFIC BINDER FOR USE IN THE TREATMENT OF IMMUNE CHECKPOINT INHIBITOR RESISTANCE
WO 2025257588 A1
申请人: AFFIMED GMBH
优先权: 2024
WO
COMBINATION THERAPY FOR THE TREATMENT OF METASTATIC CANCER
EP 4759329 A1
申请人: ONCOMATRYX BIOPHARMA S L
优先权: 2024
EP
第 1 / 2 页
上一页
下一页
药物
反馈